SE523042C2 - Användning av komposition omfattande melatonin (5-metoxi-N- acetyltryptamin) för framställning av ett läkemedel för behandling av obstruktiv sömnapne´ (OSA) - Google Patents
Användning av komposition omfattande melatonin (5-metoxi-N- acetyltryptamin) för framställning av ett läkemedel för behandling av obstruktiv sömnapne´ (OSA)Info
- Publication number
- SE523042C2 SE523042C2 SE0004206A SE0004206A SE523042C2 SE 523042 C2 SE523042 C2 SE 523042C2 SE 0004206 A SE0004206 A SE 0004206A SE 0004206 A SE0004206 A SE 0004206A SE 523042 C2 SE523042 C2 SE 523042C2
- Authority
- SE
- Sweden
- Prior art keywords
- melatonin
- sleep
- sleep apnea
- obstructive sleep
- oral administration
- Prior art date
Links
- 208000001797 obstructive sleep apnea Diseases 0.000 title claims abstract description 10
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract description 9
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 229940088597 hormone Drugs 0.000 title claims abstract description 7
- 239000005556 hormone Substances 0.000 title claims abstract description 7
- 229960003987 melatonin Drugs 0.000 title claims abstract description 7
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims 2
- LTYDTBHSPIJPEG-UHFFFAOYSA-N 3-methyl-5,5-diphenylimidazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 LTYDTBHSPIJPEG-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VQIPHLRTEXJFLG-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-n-methoxyacetamide Chemical compound C1=CC=C2C(CCN(OC)C(C)=O)=CNC2=C1 VQIPHLRTEXJFLG-UHFFFAOYSA-N 0.000 claims 1
- 210000003254 palate Anatomy 0.000 abstract description 3
- 210000002741 palatine tonsil Anatomy 0.000 abstract description 3
- 210000002105 tongue Anatomy 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 5
- 206010041235 Snoring Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940068272 melatonin 3 mg Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 101100041688 Caenorhabditis elegans sao-1 gene Proteins 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001184 pharyngeal muscle Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
a n -u- a q nu v nu u u - . v 1 o ~ Q ~ u u» n a . a ». ~ . - n u n a a - » n o o - - n u: en: n n a n o n n o o o v »lvl I . . .~ - ,. » ~ . a ~ ~ 0 n f u .. .n ._ a." --. ~ Uppfinningens ändamäl och viktigaste kännetecken En medikamentell behandling av OSA-snarksjukdom mäste vara effektiv, billig och utan biverkningar, eftersom den skall pågå hela livet under sömnperioder, oavsett tid under dygnet.
Genom regelbundna oximetertester i samband med utprovning av mekanisk assistans, konstaterades viss pàverkan av antioxi- danter, exv. tokoferol, samt hormoner som styr sömninträdet vid bl.a. jet-lag, företrädesvis melatonin, som bildas i tallkottkörteln ur aminosyran. tryptofan med serotonin som mellansteg. Melatonin {5-metoxy-N-acetyltryptamin) intaget som insomningsmedel i làg dos, 1 - 5 mg beroende pà àlder mellan 40 - 80 är, har visat tydlig effekt pä sömnregistre- ring av' OSA-drabbade patienter i fornx av reducerat antal desaturationer samt graden av SpO2 sänkning under 90%.
Melatonin har en tydlig lángtidsverkan och ger optimal påverkan först efter flera veckors regelbundet intag.
Motsvarande avtagande effekt registreras vid upphörande intag, dock regelmässigt snabbare.
Det finns anledning förmoda att samtidigt intag av ett annat hormon DHEA (dehydroepiandosteron) kan, ge en synergistisk ökning av den önskade effekten enligt ovan, särskilt i kombination med ett adrenokortikotropt hormon ACTH som stimu lator av DHEA. Det hormonella samspelets inverkan pà det auggggmasnervsystemet, som styr automatiska, omedvetna funk- , _om andningen, njartslagen, körtelaktiviteten, resp sammandragning och utvidgning av blodkärlen, kan även antas påverka muskelspänningen i svalget, främst genom glosso- pharyngeus, n.vagus, tilläggsnerven accessorius, samt tungnerven n.hypoglossus, som försörjer tungans muskulatur.
Det är sedan länge konstaterat att en i samband med sömn- inträdet spontant förslappad tungmuskel faller mot svalgväg- gen, särskilt vid ryggläge (supine pos.), varvid luftstrupen blockeras. Aven andra delar av svalgets muskulatur förslappas (gomspene, mjuka gommen, tonsiller) och retas vid sporadisk snarkning (nödandning) till svullnad som ytterligare hindrar eller försvårar luftgenomströmningen (obstruktiv sömnapné).
Olika typer av kirurgi kan dämpa snarkljudnivàn men knappast eliminera det primära andningshindret, förslappad tungmuskeL 5 2 3 Û 4 2 âjj; -'_j-. _ a::'_ 3 Förklaring till kurvdiauram_A1 - A2 resg¿_lU_¿;ly¿.
Dessa diagram visar obehandlad OSA (obstruktiv sömnapné) SaO1 samt puls, (A1 - AZL resp. tryckassisterad IPPV (B1 - BZ). som ger normala värden på SaOa och puls.
J i Kurvdiagram melatonin 3 mg pr dag för sömn, ger likvardig sömnf kvalitet som tryckassisterad.
Diagrammen. är utförda. med BIOX. pulsoximeter samt K&Z direkt- skrivare [A1-A2.B1-B2), resp. NONIN pulsoximeter samt PROFOX dataprogram och CANON BJC skrivare (melatonin 3 mg/dag).
*EE/BE ett kontinuerliot luftväostrvck som oelastar oiafraoma och försvarar utandninoen.
Förklarande text till fia. I resp_ fich _11 vid obstruktiv sömnapné faller. särskilt vid rvoo- läoc. tungan och ev. oomspe- nen mot svalaet. varvid luftoassaoen nlockeras.
Claims (5)
1. Användning av komposition omfattande nælatonin (5- e t t metoxí-N-acetyltryptamin) för framställning av läkemedel för behandling av obstruktiv sömnapné (OSA).
2. Användning enligt kravet 1, varvid läkemedlet ingár i en beredning som är avsedd för peroral administration.
3. Användning enligt kravet 2, varvid en för en person med en álder av 40-80 är avsedd normaldos inneháller 1-5 mg melatonin.
4. Användning enligt nàgot av kraven 1 till 3, varvid melantoninet är kombinerat med DHEA-hormon (dehydro- epiandosteron).
5. Användning enligt kravet 4, varvid DHEA-hormonet är kombinerat med ATCH~hormon (andrenokortikotropt).
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004206A SE523042C2 (sv) | 2000-11-15 | 2000-11-15 | Användning av komposition omfattande melatonin (5-metoxi-N- acetyltryptamin) för framställning av ett läkemedel för behandling av obstruktiv sömnapne´ (OSA) |
| US10/248,727 US6818665B2 (en) | 2000-11-15 | 2003-02-12 | Treatment of obstructive sleep apnea |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004206A SE523042C2 (sv) | 2000-11-15 | 2000-11-15 | Användning av komposition omfattande melatonin (5-metoxi-N- acetyltryptamin) för framställning av ett läkemedel för behandling av obstruktiv sömnapne´ (OSA) |
| US10/248,727 US6818665B2 (en) | 2000-11-15 | 2003-02-12 | Treatment of obstructive sleep apnea |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE0004206D0 SE0004206D0 (sv) | 2000-11-15 |
| SE0004206L SE0004206L (sv) | 2002-05-16 |
| SE523042C2 true SE523042C2 (sv) | 2004-03-23 |
Family
ID=33161648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0004206A SE523042C2 (sv) | 2000-11-15 | 2000-11-15 | Användning av komposition omfattande melatonin (5-metoxi-N- acetyltryptamin) för framställning av ett läkemedel för behandling av obstruktiv sömnapne´ (OSA) |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US6818665B2 (sv) |
| SE (1) | SE523042C2 (sv) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024220343A1 (en) * | 2023-04-18 | 2024-10-24 | Apnimed, Inc. (Delaware) | Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007098202A2 (en) | 2006-02-16 | 2007-08-30 | Imthera Medical, Inc. | An rfid based apparatus, system, and method for therapeutic treatment of a patient |
| US20080171085A1 (en) * | 2007-01-11 | 2008-07-17 | Natrol, Inc. | Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration |
| JP2011500143A (ja) | 2007-10-09 | 2011-01-06 | イムセラ・メディカル・インコーポレーテッド | 選択的刺激のための装置、システム、及び方法 |
| CA2738479C (en) | 2008-10-09 | 2017-11-28 | Imthera Medical, Inc. | Method of stimulating a hypoglossal nerve for controlling the position of a patient's tongue |
| US20100256197A1 (en) * | 2009-04-02 | 2010-10-07 | Silver Eagle Labs Nv, Llc | Nicotine Dissolving Film With Or Without Menthol |
| US20100256215A1 (en) * | 2009-04-02 | 2010-10-07 | Silver Eagle Labs Nv, Llc | Menthol-Melatonin Dissolving Film |
| AU2010318651A1 (en) | 2009-11-10 | 2012-05-03 | Imthera Medical, Inc. | System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue |
| DK2964185T3 (da) * | 2013-03-05 | 2022-02-14 | Requis Pharmaceuticals Inc | Præparater til behandlingen af søvnrelaterede luftvejslidelser |
| US11266837B2 (en) | 2019-03-06 | 2022-03-08 | Medtronic Xomed, Inc. | Position sensitive lingual muscle simulation system for obstructive sleep apnea |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
| US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
-
2000
- 2000-11-15 SE SE0004206A patent/SE523042C2/sv not_active IP Right Cessation
-
2003
- 2003-02-12 US US10/248,727 patent/US6818665B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024220343A1 (en) * | 2023-04-18 | 2024-10-24 | Apnimed, Inc. (Delaware) | Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea |
Also Published As
| Publication number | Publication date |
|---|---|
| SE0004206L (sv) | 2002-05-16 |
| US6818665B2 (en) | 2004-11-16 |
| SE0004206D0 (sv) | 2000-11-15 |
| US20040157813A1 (en) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Riva et al. | Carbon dioxide changes during high-flow nasal oxygenation in apneic patients: a single-center randomized controlled noninferiority trial | |
| CN1950028A (zh) | 对用于调节在呼气期间的正压辅助的隔膜活动作出响应于的方法和装置 | |
| Bhandari | Noninvasive respiratory support in the preterm infant | |
| SE523042C2 (sv) | Användning av komposition omfattande melatonin (5-metoxi-N- acetyltryptamin) för framställning av ett läkemedel för behandling av obstruktiv sömnapne´ (OSA) | |
| Messineo et al. | Positive airway pressure delivery: overcoming old hurdles, exploring new frontiers | |
| Bach | Noninvasive respiratory management and diaphragm and electrophrenic pacing in neuromuscular disease and spinal cord injury | |
| Liner et al. | Ventilatory management of sleep-disordered breathing in children | |
| Kim et al. | Comparison of high-flow nasal oxygenation and standard low-flow nasal oxygenation during rigid bronchoscopy: a randomized controlled trial | |
| Tromans et al. | The use of the BiPAP® biphasic positive airway pressure system in acute spinal cord injury | |
| Honca et al. | Comparison of propofol with desflurane for laparoscopic sleeve gastrectomy in morbidly obese patients: a prospective randomized trial | |
| Rishani et al. | Treatment of severe status asthmaticus with nitric oxide | |
| Eckert et al. | Physiological phenotypes | |
| Kuk et al. | Anesthetic management for simultaneous drug-induced sleep endoscopy and maxillomandibular advancement in a patient with obstructive sleep apnea | |
| Takeshita et al. | Anesthetic management of a patient with Cornelia De Lange syndrome | |
| CN101291660A (zh) | 恢复正常呼吸节律的基于s-亚硝基硫醇的复方药品 | |
| Hillman | Treatment options for obstructive sleep apnea: general and perioperative | |
| Issa et al. | Five years’ experience with home nasal continuous positive airway pressure therapy for the obstructive sleep apnea syndrome | |
| Evans et al. | Intravenous caffeine Rescue for Postoperative Hypoventilation in a 16-year-old with trisomy 10: a case report | |
| Mani | Noninvasive ventilation for hypercapnic respiratory failure in COPD and initial post-support deterioration of pH and PaCO2 may not predict failure | |
| Shen et al. | Comparison of the ED50 propofol requirements during the insertion of laryngeal mask airway Ambu AuraFlex with Ambu AuraOnce in children undergoing strabismus surgery | |
| Guilleminault et al. | Central sleep apnea, upper airway resistance and sleep | |
| Meduri | Noninvasive positive-pressure ventilation in patients with chronic obstructive pulmonary disease and acute respiratory failure | |
| Rao | Anaesthetic and intensive care management of traumatic cervical spine injury | |
| Lotz et al. | Laryngeal tube S-II to facilitate fiberoptic endotracheal intubation in an infant with Boring-Opitz syndrome | |
| Cattai et al. | A case of acute postoperative transitory sialadenosis of the submandibular glands in a healthy dog |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |